Information Provided By:
Fly News Breaks for February 5, 2018
Feb 5, 2018 | 07:27 EDT
Leerink analyst Michael Schmidt says that Clovis' Rubraca CHMP decision could remove a small overhang in the shares while noting downside is limited. While the analyst thinks it is difficult to predict the outcome of Clovis' Rubraca MAA in the 3rd line ovarian cancer treatment setting, he believes a possible negative outcome should not materially affect Clovis' valuation or his investment thesis on the stock while a positive opinion could remove a small overhang on the stock. He reiterates an Outperform rating and $90 price target on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.